Integrating New Weight Management Therapies into Comprehensive CVD Care

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Is BMI the best indicator to identify CVD patients who can be treated with GLP-1 RAs and other weight management therapies?

In this short interview, Dr Steven Nissen (Cleveland Clinic, Cleveland, US) discusses how to determine which CVD patients will benefit most from treatment with GLP-1 RAs. He highlights how lifestyle changes are often ineffective in achieving weight loss goals, and therefore, collaboration between healthcare specialists is necessary to provide the best treatment option. Lastly, Dr Nissen stresses that patients must be aware of the adverse effects of GLP1 and GIP agonists in order to improve treatment adherence.

Interview Questions:
1. How do you determine which CVD patients are appropriate candidates for GLP-1 RAs or other weight management therapies?
2. What is your approach to setting realistic weight loss goals to achieve long-term CV benefits?
3. How would you collaborate with primary care, cardiology, and bariatric specialists?
4. What clinical outcomes do you use to measure the success of weight management interventions in CVD care, both in the short and long term?
5. What strategies do you use to improve treatment adherence?

Recorded remotely from Cleveland, 2025

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Category
Cardiology
Be the first to comment

Up Next